ALX ONCOLOGY HOLDINGS INC Deferred Tax Assets, in Process Research and Development
ALX ONCOLOGY HOLDINGS INC (ALXO) had Deferred Tax Assets, in Process Research and Development of $26.97 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-09
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $26.97M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $23.45M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $17.13M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $8.44M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $26.97M 10-K · filed 2026-03-09 |
| 2024-12-31 | $23.45M 10-K · filed 2026-03-09 |
| 2023-12-31 | $17.13M 10-K · filed 2025-03-06 |
| 2022-12-31 | $8.44M 10-K · filed 2024-03-07 |
| 2021-12-31 | $5.33M 10-K · filed 2023-03-09 |
| 2020-12-31 | $2.86M 10-K · filed 2022-02-28 |
| 2019-12-31 | $3.26M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |